NCT03045861 - Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 17, 2017

Primary Completion Date

April 23, 2018

Study Completion Date

April 23, 2018

Conditions

Infection, Human Immunodeficiency VirusHIV Infections

Interventions

DRUG

GSK2838232

GSK2838232 capsules will be supplied as swedish orange, unmarked capsule (50 mg), and white, unmarked capsules (10 mg) in high-density polyethylene bottles.

DRUG

Cobicistat

Cobicistat tablets 150 mg will be supplied as an orange, round, biconvex, film-coated tablet in bulk containers for individualized dosing.

Trial Locations (14)

32803

GSK Investigational Site, Orlando

33133

GSK Investigational Site, Miami

34982

GSK Investigational Site, Ft. Pierce

35226

GSK Investigational Site, Birmingham

48072

GSK Investigational Site, Berkley

75246

GSK Investigational Site, Dallas

75602

GSK Investigational Site, Longview

90027

GSK Investigational Site, Los Angeles

90069

GSK Investigational Site, Los Angeles

93301

GSK Investigational Site, Bakersfield

01107

GSK Investigational Site, Springfield

07102

GSK Investigational Site, Newark

M5G 2C4

GSK Investigational Site, Toronto

H2L 4P9

GSK Investigational Site, Montreal